

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE
May 12, 2021

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, May 12, 2021, via webinar, accessible to the public through the Plan's website. Quorum was present.

MEMBERS PRESENT:

David Konanc, MD, Neurologist, Raleigh Neurology Associates
Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center
Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians
Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery
Phil Seats, RPh, Retired Pharmacist
John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care

MEMBERS ABSENT:

John J. Engemann, MD, Infectious Disease Specialist, Raleigh Infectious Disease Associates, PA
Joseph Shanahan, MD, Owner, Shanahan Rheumatology & Immunotherapy

PLAN & VENDOR STAFF:

Stephanie Craycroft-Andrews, PharmD, BCACP, Sr. Clinical Pharmacist, State Health Plan, Chairperson
Caroline Smart, Sr. Director, Plan Integration, State Health Plan
Dee Jones, Executive Director, State Health Plan
Natasha Davis, Sr. Pharmacy Benefits Program Manager, State Health Plan
Renée Jarnigan, RPh, Clinical Advisor, CVS Health
Stephanie R. Morrison, PharmD, BCPS, Clinical Advisor, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

Conflict of Interest Statement

In compliance with the requirements of Chapter 138A-15(e) of the State Government Ethics Act, the Chairperson read the Plan's Ethics Awareness & Conflict of Interest Reminder to the P&T Committee members and requested that members who have either an actual or perceived conflict of interest identify the conflict and refrain from discussion and voting in those matters as appropriate. No conflicts of interest were noted.

Old Business

The Chairperson asked the P&T Committee members to review the February 2021 P&T Committee Meeting minutes, which were distributed prior to the meeting. There were no additions or corrections to the minutes, so they were approved as is.

Formulary Updates

The Chairperson introduced CVS Caremark's Clinical Advisors Heather Renée Jarnigan, RPh, & Stephanie Morrison, PharmD, BCPS whom would be presenting CVS Caremark's Quarterly Formulary Updates, effective July 1, 2021. This included additions to the formulary, drug removals, and tier movements.

Ms. Jarnigan along with Dr. Morrison identified all the new molecular entities that were being removed from CVS's New-to-Market block and would be available as covered products, along with utilization management policies that went along with the new products, formulary add-backs, line extensions, and new formulations of existing formulary products. The medications being added to the formulary are as follows: KYNMOBI; PIQRAY; SARCLISA; Accu-Chek Aviva Plus, Accu-Chek Compact Plus, Accu-Chek Guide, Accu-Chek SmartView blood glucose test strips, monitoring kits; CITRANATAL PAK ESSENCE; NATESTO; PROLENSA OPH SOL; QSYMIA; ADENOCAINE INJ 40ML; BONJESTA TAB 20-20MG; DEXMEDETOMIDINE/NACL INJ 20/5ML; TRULANCE; HEALON DUET INJ PRO; HEALON GV INJ 18MG PRO; KANJINTI; RUXIENCE; TRAZIMERA; ZIRABEV; CUTAQUIG; ELOCTATE; ESPEROCT; MAYZENT PAK STARTER; TRIPTODUR; XELJANZ SOL 1MG/ML; XTANDI TAB 40MG; XTANDI TAB 80MG; and HETLIOZ LQ SUS 4MG/ML. There was no opposition from the Committee members, so the product additions were approved as presented.

Ms. Jarnigan then explained that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following products under consideration to be excluded from the formulary starting on the effective date: CELEBREX, TRAMADOL ER CAPS, CRESEMBA CAP, NOXAFIL (TAB/SUSP/INJ), APTIVUS, INVIRASE, LEXIVA, VIRACEPT, RITUXAN, AVASTIN, HERCEPTIN, HERCEPTIN HYLECTA, ZOLADEX, TRELSTAR MIXJET, NORPACE, ATIVAN (IM SOLUTION FOR INJECTION, ORAL TABLET), RYTARY CAP, METHYLPHENID TAB ER, ZOLPIDEM SUBLINGUAL, CARISOPRODOL TAB 250MG, PROVIGIL TAB, LUPRON DEPOT, LUPRON DEPOT-PED, SEASONIQUE TAB, KUVAN, PROMETRIUM CAP, NATURE-THROID TAB, WP THYROID TAB, WESTHROID TAB, CHLORD/CLIDI CAP 5-2.5MG (NDC Specific: 11534019701; 51293069601; 51293069610; 42494040901), LIBRAX-ORIGI CAP 5-2.5MG, LACTOJEN CAP (NDC Specific 73730010130), PRILOSEC DR SUSP, ELMIRON CAP, THIOLA TAB/ THIOLA EC, LITHOSTAT TAB, FERRIPROX, CUPRIMINE, SYPRINE, DESFERAL, EXJADE, JADENU, Prenatal vitamins (all brands, except CITRANATAL), THEO-24 CAP ER, LULICONAZOLE CREAM 1%, NEO-SYNALAR, HALCINONIDE CREAM 0.1%, FLURANDRENOLIDE CREAM & LOTION (includes NOLIX), LASTACFT OPH SOL, ZERVIAE OPH SOL, TOBRADEX ST OPH SUSP, CILOXAN OINT and SOL, AZASITE OPH SOL, BROMSITE OPH SOL, NEVANAC OPH SUSP, ACUVAIL OPH SOL, FML FORTE OPH SUSP, FLAREX OPH SUSP, PRED MILD OPH SUSP, MAXIDEX OPH SUSP, FML OPH OINT, INVELTYS OPH SUSP, and BETIMOL OPH SOL. All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary.

The committee approved formulary exclusion of the proposed products as presented except for two products- RYTARY CAP and LUPRON DEPOT (non-PED forms).

RYTARY will remain unchanged and on formulary at Tier 3.

LUPRON DEPOT (non-PED forms) will also remain unchanged at this time. Concerns expressed by the committee were regarding exclusion of LUPRON DEPOT for prostate cancer, but these strengths (7.5 mg, 22.5 mg, 30 mg, and 45 mg) were already excluded as of 1/1/2019 (approved by the P&T committee on 10/23/2018). LUPRON DEPOT strengths for endometriosis or uterine leiomyomata (3.25 mg and 11.25 mg) were the only strengths not already excluded and remain on formulary at Tier 6. All LUPRON DEPOT (non-PED) strengths will be reviewed at the next P&T Committee Meeting on August 11, 2021 for final determination.

Dr. Morrison identified all the branded products that will have a change in tier from non-specialty to specialty. They included: CUPRIMINE, DEPEN TITRATAB, D-PENAMINE TAB 125MG, PENICILLAMINE, SYPRINE, THIOLA, THIOLA EC, and TRIENTINE. There was no opposition from the Committee members, so the specialty product movements were approved as presented.

Dr. Morrison identified all the branded products that will have a change in tier from preferred to non-preferred. They included: KALETRA and FIRAZYR. There was no opposition from the Committee members, so the uptiers were approved as presented.

Dr. Morrison identified all the branded products that will have a change in tier from non-preferred to preferred. They included: LONSURF, STIVARGA, FIRMAGON, SUPPRELIN LA, and AFSTYLA. There was no opposition from the Committee members, so the downtiers were approved as presented.

New Business/ Additional Comments

Dr. Robie requested that the Plan consider continuous glucose meters (CGMs) as a potential addition to the formulary. Mr. Seats and Dr. Burch also verbalized support of this proposal. Ms. Smart explained that adding CGMs to the formulary would require Board approval and that the Plan will be prepared to discuss at the next Board meeting.

Adjourn

The Chairperson addressed the Committee by thanking them for their service and informed them that the next meeting would be held on August 11, 2021 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 7:30 P.M. (EST).



Stephanie Craycroft-Andrews, Chair